glp-1 digital health startups Dr. Craig Primack talks Hims & Hers launching its own offering as demand rises What's next for GLP-1 innovation:

Instead of reporting distinct RCT results, the only data available are exploratory post-hoc analyses of hs-CRP that pool individual-level data across trials [Mosenzon et al., 2022 ( Table 1 Characteristics of the included studies

Patients were randomized to TRESIBA once daily with the evening meal or insulin glargine U-100 once daily according to the approved labeling

The general rule for all GLP-1s: A dose taken within 48 hours of your usual scheduled day is acceptable for most people

Interesting that it removes fasting and injections, that could really boost adherence

And on April 1, the Food and Drug Administration (FDA) approved Foundayo (orforglipron), a pill for adults with obesity or who are overweight and have a weight-related medical condition

Be good to yourself